Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Treasury Shares (2022 - 2024)

Historic Treasury Shares for Maxcyte (MXCT) over the last 3 years, with Q4 2024 value amounting to $1.7 million.

  • Maxcyte's Treasury Shares rose 3146.78% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year increase of 3146.78%. This contributed to the annual value of $1.7 million for FY2024, which is 3146.78% up from last year.
  • Per Maxcyte's latest filing, its Treasury Shares stood at $1.7 million for Q4 2024, which was up 3146.78% from $1.3 million recorded in Q4 2023.
  • Maxcyte's 5-year Treasury Shares high stood at $1.7 million for Q4 2024, and its period low was $643600.0 during Q4 2022.
  • In the last 3 years, Maxcyte's Treasury Shares had a median value of $1.3 million in 2023 and averaged $1.2 million.
  • Per our database at Business Quant, Maxcyte's Treasury Shares surged by 10139.53% in 2023 and then surged by 3146.78% in 2024.
  • Maxcyte's Treasury Shares (Quarter) stood at $643600.0 in 2022, then skyrocketed by 101.4% to $1.3 million in 2023, then skyrocketed by 31.47% to $1.7 million in 2024.
  • Its Treasury Shares stands at $1.7 million for Q4 2024, versus $1.3 million for Q4 2023 and $643600.0 for Q4 2022.